The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen

Trial Profile

The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs CHP-MAGE-A4 (Primary) ; Picibanil
  • Indications Cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Mar 2018 New trial record
    • 01 Mar 2018 Results (n=16) assessing predictive role of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs) in patients receiving 300 microgram of CHP-MAGE-A4 and 0.5 Klinische Einheit (KE) of OK432 published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top